CD4 and neoplasm: This was quickly followed by a report from the lab of Özlem Türeci and Ugur Sahin, which demonstrated that immunogenic tumour mutations in the ‘mutanomes’ of three separate preclinical mouse tumour models largely induced a CD4+ T cell response [38], not a CD8+ T-cell response as had been expected.